CD105, also known as endoglin, is a homodimeric transmembrane coreceptor that interacts with transforming growth factor b (TGF-b) receptors type I and III and modulates TGF-b-dependent cellular responses. 1, 2 The endoglin gene, located at 9q34.11, has been implicated in a number of diseases, such as hereditary hemorrhagic telangiectasia type 1, various cardiovascular anomalies, and different types of cancer. [3] [4] [5] Most studies in the literature involving CD105, however, have focused on the role CD105 plays in angiogenesis.
CD105 is overexpressed in tumor-associated endothelium, which modulates angiogenesis and facilitates metastasis. 5 This finding implies that CD105 has a role in tumor progression through its effects on the stroma. Expression of CD105 by malignant cells also has been documented, although uncommonly. In a recent study, Perez-Gomez et al 2 suggested that changes in CD105 expression levels in Upon completion of this activity you will be able to:
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tumor cells contribute to deregulation of TGF-b-dependent and TGF-b-independent signaling pathways and malignant progression. Based on these preclinical data, antibodies specific for CD105 have been developed and are currently being used in phase I and II clinical trials. 6 On-target effects of TRC105 (anti-endoglin antibody) administration included hypoproliferative anemia (without leukopenia or thrombocytopenia), infusion reactions, and telangiectasias that were sometimes associated with mild superficial mucosal bleeding. The anemia was believed to result from TRC105-mediated suppression of proerythroblasts, the only cells in the bone marrow known to express substantial levels of CD105. The anemia was reversible and treatable without adverse sequelae. 6 Although CD105 expression has been studied in several solid tumors, relatively little is known about CD105 expression in acute myeloid leukemia (AML). In the hematopoietic system, CD105 is normally expressed by activated monocytes, proerythroblasts, fetal early B-lineage precursor cells, and a small subset of CD34+ bright hematopoietic stem/progenitor cells in the bone marrow. 7 In this study, we used immunohistochemical analysis to assess cellular CD105 expression in bone marrow (BM) specimens involved by AML. We also correlated CD105 expression with the presence of molecular abnormalities that were assessed as part of the routine workup of these patients with AML. We show that CD105 is strongly expressed in a subset of cases of AML, particularly cases of AML with t(15;17) (q24.1;q21.2)/PML-RARA. In a subset of cases assessed for the IDH2 mutation, we also show a high frequency of the IDH2 mutation in CD105-positive AML cases.
Materials and Methods

Selection of Cases
Cases of AML were selected from the files of the Department of Hematopathology at The University of Texas MD Anderson Cancer Center from October 1, 2010, through July 31, 2011. Each case was classified according to current World Health Organization criteria. 8 Cases with inadequate BM biopsy specimens were excluded. Most cases were selected in a consecutive manner, but we also selected some less common types of AML (eg, acute erythroid leukemia, acute megakaryoblastic leukemia, and AML blast phase of a myeloproliferative neoplasm [MPN] ) to ensure that a wide variety of AML types were represented in the study group. As a control group, we selected BM biopsy specimens that were negative for any myeloid neoplasm. The patients in the control group did not have a history or clinical suspicion of AML or any other myeloid neoplasm, nor did these patients develop a myeloid neoplasm during follow-up. The study was approved by the institutional review board of the MD Anderson Cancer Center.
Immunohistochemistry
Immunohistochemical analysis was performed using formalin-fixed, paraffin-embedded tissue sections of BM biopsy specimens decalcified overnight in 5% formic acid as described previously. 9 All tissue sections underwent heatinduced antigen retrieval. The slides were stained with an antibody specific for CD105 (1:50, clone SN6h; DAKO, Carpinteria, CA).
CD105 expression was assessed in the blasts and differentiating neoplastic cells of AML cases, and the results were subdivided according to the percentage of positive cells as follows: more than 80% positive, diffusely/strongly positive; 20% to 80% positive, partially positive; and less than 20% positive, negative. Uninvolved areas of BM in AML specimens as well as control specimens were also assessed for CD105 expression by myeloid and erythroid precursors, megakaryocytes, osteoblasts, endothelial cells, and stromal cells. Morphologic analysis of the BM specimens was performed independently by 2 pathologists (Z.I.C. and C.B.-R.); very few discordant interpretations were resolved by joint review.
Conventional Cytogenetic Analysis
Whole BM aspirate samples were cultured for 24 or 48 hours using methods previously described. 10 A methanol/ glacial acetic acid fixation method was used for isolating metaphase cells. Cell suspensions were dropped on air-dried slides, placed overnight in a 60°C oven, and then subjected to G-banding by conventional methods. Twenty metaphases from each specimen were analyzed.
Molecular Detection of Mutations
Bone marrow aspirate specimens were assessed by using a polymerase chain reaction (PCR) amplification followed by Sanger sequencing to detect mutations in the isocitrate dehydrogenase genes (IDH1 and IDH2) as described previously. 11 The PCR primers were modified with the addition of the M13 sequence: forward, 5′-TGTAAAACGACGGCCAGTAGCC CATCATCTGCAAAAAC-3′, and reverse, 5′-CAGGAAA CAGCTATGACCCTAGGCGAGGAGCTCCAGT-3′. All primers were purchased from Integrated DNA Technologies (Coralville, IA). Sanger sequencing was performed using the following M13 primers: forward, 5′-TGTAAAACGACGGC-CAGT-3′, and reverse, 5′-CAGGAAACAGCTATGACC-3′.
We assessed for mutations in the RAS and KIT genes by using pyrosequencing and Sanger sequencing, respectively. The FLT-3 and NPM1 genes were analyzed for mutations using methods as previously described. 12, 13 
Results
Patient Characteristics
The study group included 119 patients with AML involving the BM. The median age of the patients was 64 years (range, 1-93 years). There were 75 males and 44 females. The AML cases represented most types recognized in the current WHO classification and are listed in ❚Table 1❚. The 45 cases of AML not otherwise specified (NOS) included the following: 6 AMLs with minimal differentiation, 12 AMLs without maturation, 5 AMLs with maturation, 7 acute myelomonocytic leukemias, 5 acute monoblastic and monocytic leukemias, 7 acute erythroid leukemias, and 3 acute megakaryoblastic leukemias. Thirteen additional BM specimens negative for AML were selected as a control group. Twelve were obtained for staging, and 1 was obtained from a patient being evaluated for Sweet syndrome.
Expression of CD105
The expression of CD105 in normal CD34-positive myeloblasts is rare, and the percentage of positive cells in 5 analyzed samples using CD34-positive blasts purified by immunomagnetic isolation strategies varied between 2% and 10% (data not shown).
CD105 was diffusely and strongly expressed by blasts in 29 (24%) cases of AML ❚Image 1❚. These cases included 9 (100%) of 9 AMLs with t(15;17)(q24.1;q21.2)/PML-RARA, 2 (100%) of 2 AMLs with t(8;21)(q22;q22)/RUNX1-RUNX1T1, 1 (100%) of 1 AML with t(6;9)(p23;q34)/DEK-NUP214, 1 (33%) of 3 therapy-related AMLs, 7 (28%) of 25 AMLs with myelodysplasia-related changes, 3 (15.8%) of 19 AMLs unclassifiable, 1 (14%) of 7 AMLs with inv(16)(p13.1q22)/ CBFB-MYH11, and 5 (11%) of 45 AML-NOS cases. The AML-NOS cases diffusely positive for CD105 included 3 (25%) of 12 AMLs without maturation and 2 (40%) of 5 AMLs with maturation.
Of the remaining AML cases, 36 were partially positive and 54 were completely negative. The AML cases partially positive for CD105 included 12 AML-NOS, 8 AML-myelodysplasia-related change (MRC), 6 AML blast phase of an MPN, 5 recurrent or refractory AMLs, 3 AMLs with inv(16) (p13.1q22)/CBFB-MYH11, and 2 therapy-related AMLs.
In the group of 13 control BM specimens, 2 (15.4%) showed a subset (20%-50%) of myeloid precursors and monocytes variably positive for CD105. These 2 BM specimens included 1 from a patient being staged for follicular lymphoma and 1 from a patient being evaluated for Sweet syndrome.
Correlation With Messenger RNA Level
To correlate CD105 protein expression with its messenger RNA (mRNA) level, we plotted CD105 gene expression in hematopoietic cells at different maturation stages and AML subtypes based on curated microarray data using HemaExplorer (http://servers.binf.ku.dk/hemaexplorer/) ❚Figure 1❚. 
Correlation With Molecular and Cytogenetic Findings
Twenty-one of 29 AML cases with diffuse/strong CD105 overexpression were tested for the IDH2 mutation. Mutations were identified in 9 (42%) cases, including 4 (57%) of 7 AML-MRC, 3 (50%) of 6 AML-NOS, 1 (50%) of 2 AML unclassifiable, and 1 (100%) of 1 therapy-related AML. In all 9 cases, the IDH2 mutation was a CGG to CAG mutation in exon 4, codon 140 (R140Q) ❚Image 2❚. IDH2 mutations also were identified in 3 (27%) of 11 partially CD105-positive and 4 (14%) of 29 CD105-negative AML cases tested. Statistical analysis by 2-sided c 2 test showed a significant correlation between diffuse/strong CD105 staining and IDH2 mutation (P = .004). Other mutations identified in the cohort of 29 AML cases diffusely and strongly positive for CD105 included FLT-3 internal tandem duplication (3/20, 15%), 6 to 9 base pair deletions of CEBPA (2/20, 10%), an IDH1 mutation (n = 1), and an NPM1 exon 12 mutation (1/20, 5% 
Discussion
To our knowledge, this is the first report that has used immunohistochemistry to assess CD105/endoglin expression in different types of AML. We show that certain types of AML are more likely to be diffusely and strongly positive for CD105, particularly AML with t(15;17)(q24.1;q21.2)/ PML-RARA, which was well represented in the study group.
Although relatively few cases of AML with t(8;21)(q22;q22)/ RUNX1-RUNX1T1 and AML with t(6;9)(p23;q34)/DEK-NUP214 were studied, all of these cases also were diffusely positive for CD105. Subsets of cases of AML-NOS with maturation and AML without maturation, but not in AMLs with minimal differentiation, were also diffusely CD105 positive, suggesting an association between maturation and CD105 expression in AMLs, but this observation did not reach statistical significance. Our analysis of CD105 expression from published microarray data on cytogenetically characterized human AML cases showed that the CD105 mRNA level is consistently downregulated in cases with the cytogenetic features that we found associated with strong staining of the CD105 protein. Analyses of the relationship between mRNA expression and protein abundance values are complex. The statistically significant correlations between the CD105 mRNA levels and the cytogenetic features in these large studies suggest that these findings are not likely to be random. [14] [15] [16] [17] The underlying mechanisms are unknown.
In normal hematopoiesis, endoglin protein is normally expressed by activated monocytes, proerythroblasts, and a small subset of CD34+ bright hematopoietic stem/progenitor cells. Only a few studies in the literature have focused on CD105 expression in hematolymphoid neoplasms. Catchpoole and colleagues, 18 who performed a gene expression profiling study of childhood acute lymphoblastic leukemia (ALL), singled out CD105 as being associated with a poorer outcome. In a study using flow cytometry to assess cases of myelodysplastic syndrome, Della Porta and colleagues 19 observed that CD105 was expressed in dysplastic erythroid cells and suggested that expression correlated with the degree
❚Image 2❚ Case of acute myeloid leukemia with myelodysplasia-related changes. A, Note that the blasts show strong, diffuse CD105 expression. Negative cells are erythroid precursors, megakaryocytes, and histiocytes. B, Detection of an IDH2 mutation, CGG→CAG (R140Q), in the same patient.
be as high as 25% in cases of AML-MRC. 29 We did not detect an association between CD105 expression and IDH2 mutation in cases of AML-MRC in this study. IDH2 mutations are detected most often in cases of AML with a normal karyotype or in the intermediate cytogenetic category, and they can occur with the NPM1 mutation. 27 Patients with intermediate-risk AML who are negative for FLT3-ITD mutations and have both NPM1 and IDH1 or IDH2 mutations have an improved overall survival as compared with patients who have mutant NPM1 and wild-type IDH1 and IDH2. 30 Two different mutations in the IDH2 gene have been reported in AML: nucleotide changes in codon R140 or R172; the latter is associated with poorer outcome. 22 In this study, all strong/diffuse CD105-positive cases of AML with the IDH2 gene mutation were of the R140 type. Based on the diffuse CD105 expression in all 9 cases of AML with t(15;17) and 2 cases of AML with t(8;21), we expected a higher frequency of IDH2 mutations. However, our data are incomplete since only 3 cases of AML with t(15;17) were tested for the IDH2 mutation, and all were negative. In the literature, the association between IDH2 mutation with AML with t(15;17) has varied from 0% to 16.7%. 26, 27, 31 It is of interest that endothelial cells in BM involved by AML did not express CD105, even when CD105 was strongly expressed by AML blasts, perhaps reflecting the of dysplasia and the presence of ring sideroblasts. Lo Pardo and colleagues 20 also studied CD105 expression by flow cytometry in a group of hematolymphoid neoplasms and found that CD105 was expressed in 36% of AMLs and 77% of B-cell ALLs. Lo Pardo et al also suggested that CD105 expression correlated with the expression of CD34, CD117, and CD126 in AMLs.
An unexpected finding in the current study is a statistically significant association between diffuse and strong CD105 expression by AML blasts and the IDH2 R140Q mutation. The IDH2 gene, located at chromosome locus 15q26.1, encodes for a mitochondrial enzyme that is important for energy production and cell metabolism. Isocitrate dehydrogenase catalyzes oxidative decarboxylation of isocitrate into a-ketoglutarate by using nicotinamide adenine dinucleotide (NAD) or NAD phosphate (NADP) as a cofactor to generate NADH or NADPH, respectively. 21 The IDH2 mutation has been described in a subset of AML cases and at a lower frequency in myelodysplastic syndromes and MPNs . [22] [23] [24] [25] [26] The mutation alters the enzyme function, leading to accumulation of 2-hydroxyglutarate, global DNA hypermethylation, and interruption of hematopoietic cell differentiation. 27, 28 The frequency of IDH2 mutations in newly diagnosed AML cases is reported to range from 1% to 19% 27 AML, acute myeloid leukemia; MRC, myelodysplasia-related changes; ND, not done; NOS, not otherwise specified; +, positive; -, negative.
proper hematopoietic development and may regulate bone morphogenic proteins (mainly BMP2/4) and TGF-b in early hematopoiesis. Endogenous TGF-b is a critical factor for the maintenance of CD34+ bright /CD105+/CD90+ bright /CD38-immaturity acting through positive modulation of both CD105 and CD34 molecules. 39 Although we did not measure soluble endoglin levels, other investigators have shown that high levels of soluble CD105 in myeloid malignancies correlate with a lower level of TGF-b and a high cellular proliferation rate. 40 It is therefore possible that deregulations of endoglin and TGF-b/BMP signals in a subset of AML cases may play a role in the recapitulation of the embryonic state. The correlation between CD105 overexpression and IDH2 R140Q mutation is intriguing but needs to be evaluated in a larger patient cohort. In summary, we have shown that CD105/endoglin is diffusely and strongly expressed in a subset of AML cases. We also have shown that CD105 expression by AML is significantly associated with the presence of the IDH2 R140Q mutation. These results provide a rationale for targeting CD105 in therapeutic trials of patients with AML. 7 The association with the IDH2 mutation, although preliminary, may be a hint for better understanding the molecular mechanisms of CD105 expression in AML.
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quiescent state of endothelial cells in the BM microenvironment. CD105 expression is known to be greatest in proliferating endothelium. The lack of CD105 expression also might be related specifically to the presence of AML in the BM. In contrast with solid tumors, myeloid neoplasms have easy access to blood and might not need to increase their own vascularity. Henriksen et al 32 have suggested that CD105 expression by endothelial cells is, in part, tumor specific.
The role of CD105/endoglin in cancer pathobiology has been studied extensively since its recognition a decade ago. Most studies, however, have focused on the expression of CD105 within the endothelial cells associated with solid tumors. CD105 is known to be a potent angiogenic factor and is strongly expressed in tumor-associated endothelium of solid tumors, promoting their survival and metastasis. A few reports have described CD105 expression within in situ and invasive carcinoma cells. In vitro studies have shown that CD105 inhibits cell motility and invasion of prostate cancer cells, and its loss is associated with prostate cancer progression. 33 , 34 Kassouf et al 35 used immunohistochemistry to show that neoplastic prostatic epithelial cells are positive for CD105 in more than half of prostatic intraepithelial neoplasia (PIN) cases and in 77% of cases of invasive prostatic carcinoma. The patterns of positivity, as well as the degree of vascularity, were stronger in invasive tumors than in PIN, which might reflect a role for CD105 in tumor progression. Henriksen et al 32 showed that both normal and malignant ovarian epithelial cells express CD105 and that the degree of expression correlates well with tumor progression and overall survival. In a larger study by Bock and colleagues, 36 ovarian carcinomas expressed CD105, and the pattern of expression was stronger in primary tumors than in metastatic foci, as well as stronger in tumors from patients previously treated with chemotherapy than in patients without therapy. Davidson et al 37 also described CD105 expression in breast carcinoma cells. In aggregate, the data suggest that CD105 is widely expressed in many malignant tumors. As a result, therapeutic antibodies specific for CD105 have been developed and are being used in clinical trials for patients with solid tumors and could be a potential therapeutic target. 6 Knowing that therapeutic antibodies for CD105 are becoming available, we thought patients with AML could possibly benefit from their use and hence the reason for this study.
The explanation for the cellular endoglin overexpression in a subset of patients with AML, which seems to be related to the type of AML, cannot be determined based on the data in this study. We believe that hypoxia is an unlikely explanation, since the BM endothelial cells were not actively proliferating and lacked CD105 expression. As AML is an acute and rapidly growing neoplasm, perhaps CD105 expression by endothelial cells is unnecessary to tumor progression. A recent study by Borges and colleagues 38 showed that CD105 is needed for
